CAJ | 학술논문

目的探讨赫赛汀联合多西紫杉醇用于局部晚期乳腺癌新辅助化疗的近期疗效及不良反应.方法16例经病理证实为局部晚期乳腺浸润性导管癌患者接受赫赛汀(第1周期8 ms/kg,第2～4周期6ms/ks;静脉注射90 min,第1天)加多西紫杉醇(多西紫杉醇75 ms/m2静脉注射60 min,第2天)术前化疗,3周为1个周期,共4个周期;术前化疗后接受乳腺癌改良根治术或保乳根治术.结果 16例患者总有效率为87.5%,临床完全缓解率为56.3%,病理完全缓解率为25.0%;KPS评分均得到较大改善;主要不良反应为骨髓抑制和胃肠道反应,未出现心脏毒性.结论赫赛汀联合多西紫杉醇用于局部晚期乳腺癌新辅助化疗有较高的有效性和安全性,值得临床进一步探讨,最终结论需大样本的研究结果.
목적 탐토혁새정연합다서자삼순용우국부만기유선암신보조화료적근기료효급불량반응.방법16례경병리증실위국부만기유선침윤성도관암환자접수혁새정(제1주기8 ms/kg,제2～4주기6ms/ks;정맥주사90 min,제1천)가다서자삼순(다서자삼순75 ms/m2정맥주사60 min,제2천)술전화료,3주위1개주기,공4개주기;술전화료후접수유선암개량근치술혹보유근치술.결과 16례환자총유효솔위87.5%,림상완전완해솔위56.3%,병리완전완해솔위25.0%;KPS평분균득도교대개선;주요불량반응위골수억제화위장도반응,미출현심장독성.결론혁새정연합다서자삼순용우국부만기유선암신보조화료유교고적유효성화안전성,치득림상진일보탐토,최종결론수대양본적연구결과.
Objective To investigate the efficacy and adverse effect of herceptin combined with docetaxel in patients with localized advanced breast cancer. Methods 16 patients with localized advanced breast cancer were treated with herceptin (8 mg/kg in the first cycle and 6 mg/kg from 2 to 4 cycles,d1) and docetaxel (75 mg/m2 ,d2) for 4 cycles. Three weeks were taken as a cycle. Following chemotherapy, the patients underwent improved radical operation of breast cancer or radical operation of preserving breast. Results The overall response rate (oRR) was 87.5%. The complete clinical remission rate (cCR) was 56. 3%. The complete pathologic remission rate (pCR) was 25.0%. The mainly adverse effects were bone marrow depression and gastrointestinal toxicity. Conclusion The regimen of herceptin combined with docetaxel is effective and can be well-tolerated by patients with localized advanced breast cancer. It shows promising prospect in clinical application.